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Screening of Urea Cycle Disorders
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Johannes Ha¨berle,5 and Carlo R. Largiade`r1*
BACKGROUND: Molecular genetic testing is commonly
used to confirm clinical diagnoses of inherited urea cycle
disorders (UCDs); however, conventional mutation
screenings encompassingonly the coding regionsof genes
may not detect disease-causing mutations occurring in
regulatory elements and introns.Microarray-based target
enrichment and next-generation sequencing now allow
more-comprehensive genetic screening. We applied
this approach to UCDs and combined it with the use of
DNA bar codes for more cost-effective, parallel analy-
ses of multiple samples.
METHODS: We used sectored 2240-feature medium-
density oligonucleotide arrays to capture and enrich a
199-kb genomic target encompassing the complete
genomic regions of 3 urea cycle genes,OTC (ornithine
carbamoyltransferase), CPS1 (carbamoyl-phosphate
synthetase 1, mitochondrial), and NAGS (N-
acetylglutamate synthase). We used the Genome Se-
quencer FLX System (454 Life Sciences) to jointly ana-
lyze 4 samples individually taggedwith a 6-bpDNAbar
code and compared the results with those for an indi-
vidually sequenced sample.
RESULTS: Using a low tiling density of only 1 probe per
91 bp, we obtained strong enrichment of the targeted
loci to achieve 90% coverage with up to 64% of the
sequences covered at a sequencing depth10-fold.We
observed a very homogeneous sequence representation
of the bar-coded samples, which yielded a 30% in-
crease in the sequence data generated per sample,
compared with an individually processed sample.
Heterozygous and homozygous disease-associated
mutations were correctly detected in all samples.
CONCLUSIONS: The use of DNA bar codes and the use of
sectored oligonucleotide arrays for target enrichment
enable parallel, large-scale analysis of complete
genomic regions for multiple genes of a disease path-
way and for multiple samples simultaneously. This ap-
proach thus may provide an efficient tool for compre-
hensive diagnostic screening of mutations.
© 2010 American Association for Clinical Chemistry
Urea cycle disorders (UCDs)6 are inborn errors of me-
tabolism caused by a reduced or absent activity of en-
zymes involved the transfer of nitrogen from ammonia
to urea (1 ). Because the urea cycle is the only pathway
capable of metabolizing excess nitrogen, such enzyme
defects lead to toxic hyperammonemia, which usually
has a high morbidity and mortality (2 ). The urea cycle
consists of 6 nuclear genome–encoded enzymes, 3 of
which are located in the mitochondrial matrix: CPS17
(carbamoyl-phosphate synthetase 1, mitochondrial),
NAGS (N-acetylglutamate synthase), and OTC (orni-
thine carbamoyltransferase). With the aid of the allo-
steric activator N-acetylglutamate synthesized by
NAGS, CPS1 catalyzes the transformation of ammonia
to carbamoyl phosphate. OTC subsequently metabo-
lizes carbamoyl phosphate to citrulline, which is then
converted to urea in the cytosol.
Whereas measurements of intermediary metabo-
lites are primarily used to establish diagnoses of inborn
UCDs, genetic mutation testing is commonly used to
confirm diagnoses. Today, the standard approach to
mutation screening for OTC, CPS1, or NAGS defi-
ciency encompasses the sequencing of coding regions
and splice sites; however, this approach detects a
disease-causing mutation in only about 80% of pa-
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tients with OTC deficiency (3 ). This fact, together with
the recent identification of deleterious mutations lo-
cated deep within the introns of the OTC gene (4, 5 ),
demonstrates the need for new tools for mutation
screening that include investigation of the noncoding
regions of genes. Furthermore, for very large genes
such asCPS1 (120 kb encompassing 38 exons), being
able to conduct a comprehensive analysis at the
genomic DNA level without the need for numerous
PCR amplifications of single exons could greatly sim-
plify the search for disease-causing mutations. Finally,
given that NAGS supplies the cofactor required for the
CPS1-catalyzed reaction, biochemical measurements
of intermediary metabolites cannot be used to distin-
guish between NAGS and CPS1 deficiencies (2 ). Simi-
larly, assays of biochemical markers can yield ambigu-
ous results in late-onset forms of OTC deficiency
(6–8). In such cases, the ability to simultaneously
screen multiple genes potentially involved in a sus-
pected metabolic disorder could avoid invasive proce-
dures required for direct measurements of enzyme ac-
tivity (9, 10) and thereby improve diagnostic
efficiency.
With the development of next-generation se-
quencing (NGS) technologies, it is nowpossible to gen-
erate large amounts of sequence data at lower cost and
with less effort (11), offering new possibilities for diag-
nostic mutation screening (12–16). To analyze specific
regions in complex eukaryotic genomes with NGS,
however, requires prior selection or amplification of
the target regions. PCR, the most widely applied
method for this purpose, has strong limitations in
terms of multiplexing grade and product length that
make it unsuitable for large or dispersed genomic tar-
gets. Therefore, hybridization to complementary oli-
gonucleotide probes, either on DNA microarrays (17–
19) or in solution (20), has recently been successfully
used to enrich genomic regions for NGS.
Given that the amount of sequence data that most
NGS instruments generate in a full sequencing run is
much larger than the amount required for reliable vari-
ant detection in moderately sized (200 kb) targets, an-
alyzing multiple samples in parallel via the use of DNA
bar codes might allow optimization of the cost-
effectiveness of this approach (13, 21). The addition of
a specific sequence tag (DNA bar code) to each sample
enables pooled processing of samples (thereby reduc-
ing time andmaterials), as opposed to physical separa-
tion (e.g., sectoring of sequencing plates), which is also
associated with a reduction in the total number of se-
quences generated (13, 21).
Most microarray-based sequence capture (MSC)
protocols have used high-density oligonucleotide ar-
rays containing up to 385 000 capture probes to enrich
genomic targets (18, 22). We assessed the suitability of
the use ofmedium-density arrays containing only 2240
oligonucleotide probes combined with a long-read
NGS technology for MSC and the use of DNA bar
codes for the parallel analysis ofmultiple samples.With
inherited UCDs as a model, we investigated a 199-kb
region that encompasses the complete genomic se-
quences of OTC, NAGS, and CPS1. This approach en-
abled (a) the detection of mutations not only in coding
regions but also in regulatory and intronic regions, (b)
the comprehensive investigation at the genomic DNA
level of a large gene comprisingmany exons; and (c) the
simultaneous investigation of 3 genes involved in the
same disease pathway.
Materials andMethods
DNA SAMPLES
We analyzed a total of 4 DNA samples—2 samples
taken from carriers of disease-causing OTCmutations
(samplesOTCAandOTCB) and 2 samples fromCPS1-
deficient patients (samples CPSA and CPSB). In all pa-
tients, the disease-associated mutations had previously
been detected with Sanger sequencing. The patients or
their parents provided informed consent for the ge-
netic studies in this initial analysis. Subsequently, sam-
ples were irreversibly anonymized, andmutations were
not known to the investigator. As a negative control, we
also sequenced 1 sample without performing the MSC
hybridization (sample UNC). We used DNA bar codes
to analyze samples CPSA, CPSB, OTCB, and UNC,
whereas we analyzed sample OTCA without bar codes
by use of a sectored 454 picotiter plate in a comparison
of both approaches.
ARRAY DESIGN AND SYNTHESIS
The target region encompassed the entire genomic re-
gions of OTC, NAGS, and CPS1, along with 6 control
loci for the assessment of enrichment efficacy (see
Methods in the Data Supplement that accompanies
the online version of this article at http://www.
clinchem.org/content/vol57/issue1). Probes were de-
signed by tiling the target regions with probes of
50–60 bp, which were selected on the basis of melt-
ing temperature (Tm), complexity, secondary struc-
ture, GC content, and specificity.We ultimately used
a total of 2240 capture probes resulting in a mean
tiling density of 1 probe per 91 bp. There was no
probe redundancy in the final array design. The
Methods section in the online Data Supplement pro-
vides a more detailed description of the probe de-
sign. Arrays containing 4 independent 2240-feature
microarrays on a single slide were synthesized on a
CustomArray Synthesizer (CombiMatrix).
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SAMPLE PREPARATION AND MSC HYBRIDIZATION
The Methods section in the online Data Supplement
provides a detailed description of sample preparation
and array hybridization procedures. In brief, 20 g of
whole genome–amplified DNA was fragmented by
nebulization to fragments of approximately 500–600
bp, blunt-ended, and ligated to universal adaptors. The
adaptor-ligated DNA was hybridized for 64 h at 42 °C
to one of 4 independent array sectors for samples
CPSA,CPSB, andOTCBwith hybridization conditions
that were slightly modified compared with those for
sampleOTCA (seeMethods in the onlineData Supple-
ment). We washed the hybridized arrays, eluted the
captured DNA with molecular-grade water at 95 °C,
and amplified the DNA with the universal adaptors as
primers. For DNA bar coding of samples CPSA, CPSB,
OTCB, and UNC, we used primers containing a
sample-specific 6-bp sequence tag (21) at the 5 end.
We assessed enrichment success by using real-time
quantitative PCR of the control loci and comparing
samples taken before and after hybridization (see
Methods in the online Data Supplement).
454 SEQUENCING AND DATA ANALYSIS
A 454-sequencing service provider (Microsynth) pre-
pared a single sequencing library from the tagged and
equally pooled samples CPSA, CPSB, OTCB, and
UNC, and a separate library for sample OTCA. The
libraries were analyzed on a 454 Genome Sequencer
FLX Titanium (Roche) with half a picotiter plate for
the pooled library and one-eighth of a plate for sample
OTCA. We sorted sequence reads by bar code as de-
scribed in the online Data Supplement and mapped
them to the human genome and target regions with
GS Reference Mapper (Roche Applied Sciences) and
MOSAIK assembler software (23). Only reads with a
unique match to a chromosome containing a target
gene were used for mapping to the target sequence.
Statistical analyses were performed with the statistics
software R (24). A detailed description of these analy-
ses is given in the Methods in the online Data
Supplement.
Results
ENRICHMENT AND 454 SEQUENCING OF CAPTURED SAMPLES
The degree of enrichment for the captured samples was
estimated by quantitative PCR analysis to be between
1489-fold and 3023-fold, indicating that MSC hybrid-
ization was successful (Table 1). For the pooled library
of samples CPSA, CPSB, OTCB, and UNC, we ob-
tained a total of 584 390 sequence reads and 181Mb of
sequence with a mean read length of 311 bp. Of these
sequence reads, 524 378 (90%) could be assigned un-
ambiguously to one of the samples with aid of theDNA
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bar codes. The remaining sequence reads were either
not assigned to any sample or assigned to multiple
samples because of sequencing or synthesis errors in
the bar code; these reads were therefore removed from
the analysis. All 4 samples were represented with very
similar proportions of sequence reads (range, 21%–
25%), with at least 119 664 reads obtained per sample
(Fig. 1B).
For the individually sequenced sample OTCA, we
obtained 91 688 sequence reads (20 Mb) with a mean
read length of 219 bp. For the samples from the pooled
library, 89% of all sequence reads had a unique match
in the human genome, whereas this proportion was
only 58% for sample OTCA (Table 1 and online Table
1). Of all reads with a unique match to a target chro-
mosome, between 9225 and 12 712 reads (correspond-
ing to2.8 Mb of sequence per sample) were mapped
to the target region with95% sequence identity (Ta-
ble 1) in the MSC-enriched samples, whereas only 202
reads (64 707 bp) were mapped in sample UNC.
In theMSC-enriched samples,90% of the target
region was covered by at least 1 sequence read at a me-
dian sequencing depth of 8- to 14-fold (Table 1, Fig.
1A). Sequence coverage and median sequencing depth
were lowest in sample OTCA, despite this sample hav-
ing a similar overall number of mapped base pairs (Ta-
ble 1, Fig. 1). This result indicated a more homoge-
neous sequence distribution across the target region
for samples CPSA, CPSB, and OTCB, potentially be-
cause of the slightly modified hybridization protocol
(Table 1). SampleOTCB had the highest sequence cov-
erage and sequencing depth and also had the highest
estimated enrichment (Table 1). In this sample, 79.8%
of the target sequence had a sequencing depth of 5-
fold, and 64.3% was sequenced at a depth of10-fold
(Table 2).
INTERSAMPLE REPRODUCIBILITY
The 3 samples captured with an identical protocol
(CPSA, CPSB, and OTCB) had very similar distribu-
tions of sequencing depth, which demonstrated the
Fig. 1. Sequencing depth and sequence representation.
(A), Distribution of sequencing depth for the 5 analyzed samples. (B), Detailed view excluding sample UNC. (C), Sequence
representation of the 4 DNA–bar-coded and pooled samples obtained from a single sequencing library. The pie chart has the
same CPSA, CPSB, OTCB, and UNC data as (A) and indicates the number of reads for each bar-coded sample. NA, nonassigned
sequences.
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high intersample reproducibility of the MSC proce-
dure (Table 2, Fig. 2). The 3 samples had correlation
coefficients for sequencing depth that ranged from0.84
to 0.86 (see Table 2 in the online Data Supplement),
and 82.6% of the nucleotide positions in the target se-
quence with a sequencing depth10-fold in the least-
enriched sample (CPSB) were sequenced at the same
depth or greater in the other samples (Table 2).
DIFFERENCES IN ENRICHMENT BETWEEN THE 3 TARGET GENES
The target genes had similar sequence coverages, but
NAGS had the lowest median sequencing depth, indi-
cating a less successful enrichment for this gene (Table
1). Comparison of the capture probes for the target
genes revealed that NAGS probes had, on average, a
higher GC content, a shorter length, a higher Tm, and a
lower tiling density than probes for OTC or CPS1 (see
Table 3 in the online Data Supplement), suggesting
thatNAGS has sequence properties that are more chal-
lenging for MSC and NGS.
Furthermore, we observed that OTC had a lower
median sequencing depth than CPS1 in sample CPSA.
Because sample CPSAwas the only sample from amale
patient, the lower sequencing depth in the OTC gene
can be explained by the patient’s hemizygosity for this
X-linked gene.
NONSPECIFIC SEQUENCE MAPPING
Theamountof sequencemapped to the target regionswas
inversely correlatedwith the proximity to a capture probe
in theMSC-enriched samples; however, no such correla-
tionwas observed in sampleUNC, a finding that demon-
strates the specificity of the MSC approach (Fig. 3A). In
the MSC-enriched samples, 91% of the mapped se-
quence data aligned on or within 100 bp of a capture
probe,whereas in sampleUNC, a large proportion (42%)
of the aligned sequences mapped to regions with no cap-
ture probe within 100 bp (Fig. 3A). A majority (94%) of
these sequences mapped to a specific section of approxi-
mately 1800 bp in CPS1, a region for which no capture
probes had been designed (Fig. 3B). We had rejected all
probes tested for this region because of substantial simi-
larities withmultiple other regions in the human genome
(Fig.3B).This findingsuggests that the sequencesaligning
to this section were not captured by MSC but were
wrongly aligned from other genomic regions because of
the high sequence similarity.
MUTATION DETECTION IN MSC-ENRICHED TARGET REGIONS
AllOTC,NAGS, andCPS1 exonswith flanking intronic
and untranslated regions were screened for potential
sequence variants, and parts of these screened regions
were resequenced with Sanger technology (see Table 4
in the online Data Supplement). With both technolo-
gies, we sequenced a total of approximately 34 kb, of
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which 20 kb was covered10-fold in the NGS analysis
and 27 kb was sequenced at a coverage of5-fold (Ta-
ble 3). We correctly identified the previously detected
disease-associated mutations in all 4 samples, includ-
ing 4 heterozygous substitutions, 1 homozygous sub-
stitution, and 1 heterozygous 3-bp deletion (see Table 5
in the online Data Supplement). For heterozygote call-
ing, we assessed 2 different cutoffs for the proportion of
variant alleles observed in the NGS data (Table 3). For
both cutoffs, most (87%) of the detected sequence
variants in regions with a sequencing depth 10-fold
were confirmedwith Sanger technology, with themore
stringent cutoff (cutoff B) producing an increased pos-
itive predictive value but a reduced sensitivity (Table
3). Overall accuracy tended to be increased when the
sequencing-depth threshold was increased, although
the total number of variants assessed at higher depths
was too small for reliable statistical inference. In re-
gions with a sequencing depth between 5-fold and
9-fold, we observed a higher error rate for heterozy-
gous, but not for homozygous, variants (Table 3). Fi-
nally, 57 (92%) of 62 positions deviating from the ref-
erence sequence at a depth of10-fold, whichwere not
analyzed with Sanger sequencing, had a dbSNP record
(25), a result again indicating a low false-positive rate
for the NGS data. Insertions or deletions in or close to
homopolymer regions of4 repeats of the same base, a
threshold selected by visual inspection of the sequenc-
ing data, were not considered in all analyses. In such
regions, we confirmed only 2 of 10 putative variants
with Sanger sequencing, indicating a high false-
positive rate.
Discussion
In this study, we successfully usedmedium-density oli-
gonucleotide arrays for MSC and NGS and used sec-
tored arrays and DNA bar coding to analyze multiple
samples in parallel. Capturing the complete genomic
regions ofOTC,CPS1, andNAGS permitted the simul-
taneous and comprehensive screening for disease-
causingmutations in 3 genes involved in inbornUCDs.
Fig. 2. Reproducibility of the MSC procedure.
(A), Reproducibility of sequencing depth in the OTC gene for 3 captured, tagged, and simultaneously analyzed samples. (B),
Reproducibility of sequencing depth in the CPS1 gene for the same 3 samples.
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MUTATION DETECTION IN MSC-ENRICHED TARGET REGIONS
We correctly identified all disease-causing mutations
in the target genes in all samples. Furthermore, Sanger
sequencing confirmed the majority of additional poly-
morphisms detected in the screened regions, a finding
demonstrating the potential of this approach for mu-
tation detection, given a sufficient sequencing depth.
We obtained a high accuracy with a relatively low
threshold depth (10-fold) for variant detection. We
also reliably detected homozygous variants at a depth
of 5-fold to 9-fold, indicating that a lower threshold
could potentially be used for hemizygous regions, such
as X-linked genes inmale patients. As demonstrated by
the different cutoffs assessed for calling heterozygous
variants, the threshold proportion of variant alleles also
strongly influenced the sensitivity and specificity of
mutation detection. A higher number of false positives
was observed with a threshold of 20% variant alleles,
whereas increasing this threshold to 30% produced a
loss in sensitivity due to 1 undetected heterozygous
mutation. Altogether, we observed only 1 false positive
and 1 false negative in 19 615 analyzed base pairs at a
30% threshold and a sequencing depth of 10-fold
(for a more detailed discussion, see the Supplementary
Materials in the online Data Supplement). Diagnostic
applications, however, require a higher threshold of se-
quencing depth to increase the accuracy of heterozy-
gote calling (16).
Further refinement of standard thresholds and re-
liable estimation of error rates for mutation discovery
with NGS requires the validation of larger numbers of
putative variants with Sanger sequencing (14). In the
Fig. 3. Specificity of the MSC procedure and nonspecific sequence mapping.
(A), Correlation of the sequence data obtained with the distance to the capture probe. (B), Nonspecific sequence mapping in
a 1800-bp region in CPS1 and similarities of the tested capture probes for this region to sequences in the human genome
(consecutive probes with 10 C-BLAST hits spanning 200 bp are shown).
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clinical setting, confirmation of putative disease-
associated mutations with Sanger sequencing is thus
strongly advisable until these standards become estab-
lished. In this context, consideration also needs to be
given to the increased overall number of sequence vari-
ants that will be detected when larger genomic regions
are investigated (13). Filtering strategies that identify
known polymorphisms and predict potential func-
tional effects are required to distinguish between po-
tential disease-causing mutations and benign variants
(26).
DNA BAR CODING
We observed no reduction in sequence quality or in-
crease in error rate due to the pooling of tagged sam-
ples, as indicated by the longer read lengths obtained
for the bar-coded samples and the very low estimates of
error rate for all samples. In contrast, compared with
the individually analyzed sample OTCA, use of DNA
bar codes yielded a 30% increase in the number of
sequence reads per sample, which reduced the cost per
nucleotide sequenced. Furthermore, only a single se-
quencing library needed to be prepared for 4 samples.
Having only a single library preparation substantially
reduced the costs for library preparation and thus sig-
nificantly improved the cost-effectiveness of the MSC/
NGS approach. In the future, with the continuing in-
crease in read lengths of NGS technologies and the
upcoming third-generation instruments promising
even longer sequence reads (27), parallel analyses of
larger numbers of samples will become possible, be-
cause each samplewill require fewer reads for sufficient
coverage.
REDUCED TILING DENSITY AND THE ADVANTAGE OF LONG
READ LENGTHS
Our use in this study of a single MSC hybridization to
an oligonucleotide array containing only 2240 capture
probes produced enrichment efficacies similar to those
obtained with protocols that used 100-fold more
probes or that used 2 successive MSC hybridizations
for a similarly sized target (12, 18, 22, 28, 29). Our re-
sults have thus demonstrated the suitability of this ap-
proach for capturingmoderately sized targets (approx-
imately 200 kb). Despite the low tiling density, our
protocol also yielded enrichment uniformities similar
to those reported for other studies (12, 18, 22, 28, 29).
Table 3. Results for the use of MSC and NGS for detecting a variant position deviating from the reference
sequence, compared with Sanger sequencing results.
Varianta
Deviant
allele, %b TP,c n FP, n FN, n TN, n Sensitivity Specificity PPV NPV
Depth 20-fold
Homozygous 80 3 0 0 11 727 1 1 1 1
Heterozygous, cutoff A 20–80 11 1 0 11 718 1 0.99 0.92 1
Heterozygous, cutoff B 30–70 11 0 0 11 719 1 1 1 1
Depth 15-fold
Homozygous 80 6 0 0 15 617 1 1 1 1
Heterozygous, cutoff A 20–80 15 3 0 15 605 1 0.99 0.83 1
Heterozygous, cutoff B 30–70 15 1 0 15 607 1 0.99 0.94 1
Depth 10-fold
Homozygous 80 8 0 0 19 607 1 1 1 1
Heterozygous, cutoff A 20–80 21 3 0 19 590 1 0.99 0.88 1
Heterozygous, cutoff B 30–70 20 1 1 19 593 0.95 0.99 0.95 0.99
Depth 5-fold
Homozygous 80 16 0 0 26 646 1 1 1 1
Heterozygous, cutoff A 20–80 23 8 2 26 629 0.92 0.99 0.74 0.99
Heterozygous, cutoff B 30–70 22 4 3 26 633 0.88 0.99 0.85 0.99
a The different proportions of deviant alleles (i.e., cutoff A or B) used for heterozygote calling; given as percentages in column 2.
b Percentage of deviant alleles observed in the NGS data used for genotype calling.
c TP, true positive (variant confirmed by Sanger sequencing); FP, false positive (variant not confirmed by Sanger sequencing); FN, false negative (variant not detected
in NGS analysis but observed in Sanger sequencing); TN, true negative (no deviation from reference sequence with both sequencing methods); PPV, positive
predictive value; NPV, negative predictive value.
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Further studies are required, however, to determine the
upper limit of MSC target size with such a low probe
number. This successful enrichment with a much
lower tiling density may be explained by the higher
binding capacity of capture probes to the different ar-
ray surface we used, compared with other oligonucle-
otide arrays (see discussion in the Supplementary Ma-
terials in the online Data Supplement).
Besides platform-specific issues, which require ex-
perimental validation, reduced tiling densities may
represent a platform-independent approach to effi-
ciently capture long templates for NGS technologies
that generate long sequence reads. Because of their
lower diffusion rates and increased intramolecular base
pairing, the hybridization of long DNA fragments to
capture probes is expected to be inferior to that of short
fragments (30). Use of a high tiling density for target
enrichment may therefore produce a general bias to-
ward shorter captured fragments, reducing the overall
sequence read length. Although a more controlled
DNA-fragmentation processmay overcome this bias in
part, one can expect that a smaller number of short
fragments will overlap with capture probes at a lower
tiling density. This feature has the potential to reduce
this bias and enable more longer fragments to be cap-
tured and sequenced. Comparative investigations with
other target-enrichment systems are needed, however,
to address this issue in more detail.
The possibility of obtaining long sequence reads
may be of particular advantage for diagnostic applica-
tions. In addition to the less computationally inten-
sive alignment procedure and a higher sensitivity for
detecting larger insertions or deletions (12 ), the use
of a long-read NGS technology improves the direct
observation of haplotype structures, because each
NGS read displays the gametic phase directly.
Longer read lengths produce longer stretches of
known gametic phase, simplifying haplotype infer-
ence and thus providing valuable information for
diagnostic applications (31 ).
TARGET SEQUENCE PROPERTIES AND NONSPECIFIC MAPPING
Despite the strong overall enrichment we observed in
this study, enrichment efficacy varied, depending on
the genomic target. We observed only moderate en-
richment for the NAGS gene. In agreement with other
studies [e.g., (16, 20, 31)], this finding indicates that
MSC is more challenging in regions with unfavorable
target sequence properties (e.g., high GC content).
Furthermore, the amplification bias for the same re-
gions during the whole genome–amplification process
used for this protocol may have exacerbated this effect.
At present, however, this amplification stepmay be un-
avoidable in the clinical setting, where often only small
amounts of patient DNA are obtainable. Further opti-
mization of the criteria used for probe design may im-
prove enrichment in such regions, however.Moreover,
including multiple probe replicates on an array or lo-
cally increasing the tiling density for problematic re-
gions may compensate for a poorer enrichment or
potential amplification bias and thus improve enrich-
ment. Finally, further refinement of the enrichment
procedure may also improve capture efficiency in such
regions (32).
Interestingly, a substantial amount of sequences in
the uncaptured sample UNC mapped to a segment in
the target sequence that contained no capture probes
because of high sequence similarities to multiple other
regions in the genome. This finding is surprising be-
cause only sequence reads with a unique match to the
target chromosomes were used in the analysis, and it
indicates that genomic regions with many highly ho-
mologous sequences present a challenge for NGSmap-
ping algorithms. Because the sequencing depth in sam-
pleUNC in this regionwas above the threshold used for
mutation detection, such nonspecific mapping repre-
sents a potential source of false positives in a mutation
screening (12). Further refinement of mapping algo-
rithms is required to permit discrimination between
such highly similar sequences (12).
Conclusions
Our results highlight the potential of MSC combined
with NGS for diagnostic mutation screening, as we
have demonstrated for inherited UCDs. The use of
sectored arrays and the use of DNA bar codes are
independent possibilities for increasing throughput
and reducing analysis costs. This approach not only
enables the simultaneous and comprehensive inves-
tigation of multiple target genes but also facilitates
the analysis of multiple samples in parallel, greatly
simplifying the search for disease-causing muta-
tions. Finally, the ability to investigate complete
coding, intronic, and untranslated regions creates an
opportunity to increase our knowledge of genetic
variation in noncoding gene regions and its rele-
vance for inherited disorders.
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